A strategic partnership: what role for pharma in a changing NHS?
Dr Philip Schwab Director of Government Affairs, AbbVie |
Deepak Jadon Consultant Rheumatologist & Director of Rheumatology Research Unit at Addenbrooke's Hospital, Cambridge |
Richard Murray Director of Policy, King’s Fund |
Sue Thomas Chief Executive for Commissioning Excellence, Wilmington Healthcare |
Paul Midgley Director of NHS Insight, Wilmington Healthcare |
Dr Neil Bacon Chief Executive Officer, iWantGreatCare |
Jennifer Lee Director of Health Economics, Market Access, Reimbursement & Advocacy, Janssen |
Peter Huskinson Commercial Director for Specialised Commissioning, NHS England |
Key themes
Hosted by pharmaphorum and NHS experts Wilmington Healthcare, this free-to-attend half-day conference will explore how the industry can work with a fast-changing health service:
- Sustainability and Transformation Plans (STPs) are taking on powers to commission across primary, secondary and social care. How should pharma respond to this new agenda?
- How can a post-Brexit life sciences industrial strategy fit together with the NHS Five Year Forward View?
- The clinician’s perspective: meeting patient needs and introducing new medicines in a restricted budget environment
Anyone working in the UK pharmaceutical industry who needs to keep abreast of the changing NHS environment should attend, to hear directly from NHS, industry and other key stakeholders.
Please note that this agenda is likely to be updated, and additional speakers will be confirmed in the coming weeks.
Agenda
- Registration and coffee: 9.00 am – 9.45 am
- Introduction: 9.45 am – 10.00 am
- Discussion 1: 10.00 am – 11.00 am
- Q1: NHS overview – where are we now?
- Q2: STPs are taking on powers to commission across primary, secondary and social care. An update on the national progress of STPs. How should pharma respond to this new agenda?
- Q3: How can a life sciences strategy fit together with the Five Year Forward View?
- Q4: The clinician’s perspective: meeting patient needs in a budget-restricted environment
- Questions from the audience
- Coffee Break: 11.00 am – 11.15 am
- Discussion 2: 11.15 am – 12.35 pm
- Q1: Health in the time of Brexit: how can the NHS and pharma adapt and thrive?
- Q2: Improving patient outcomes in cancer
- Q3: A new deal on pricing, access and value: can the UK make the leap?
- Questions from the audience
- Summing up: 12.35 pm – 12.40 pm
- Complimentary networking lunch: 12.40 pm – 2.00 pm
- Close: 2.00 pm